Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6436032rdf:typepubmed:Citationlld:pubmed
pubmed-article:6436032lifeskim:mentionsumls-concept:C0017887lld:lifeskim
pubmed-article:6436032lifeskim:mentionsumls-concept:C0005508lld:lifeskim
pubmed-article:6436032lifeskim:mentionsumls-concept:C0302350lld:lifeskim
pubmed-article:6436032lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:6436032lifeskim:mentionsumls-concept:C0694643lld:lifeskim
pubmed-article:6436032lifeskim:mentionsumls-concept:C0699235lld:lifeskim
pubmed-article:6436032pubmed:issue1lld:pubmed
pubmed-article:6436032pubmed:dateCreated1984-12-20lld:pubmed
pubmed-article:6436032pubmed:abstractTextIn 6 healthy volunteers, intravenous infusions of nitroglycerin 4.8 and 10.6 micrograms/min yielded mean steady-state plasma concentrations of 0.5 +/- 0.02 and 0.82 +/- 0.04 ng/ml as determined by a gas chromatographic/mass spectrometric method. The plasma concentrations reached in the same subjects 17 h after application of Nitroderm TTS 5 and 10 with in vivo release rates of 3.7 and 5.7 micrograms/min were 0.28 +/- 0.01 and 0.37 +/- 0.01 ng/ml, respectively. Thus, 75% of the quantity of nitroglycerin released by the systems passed into the circulation. The inter-individual and intra-individual variations in plasma concentrations were similar for both modes of administration. The nitroglycerin-induced morphological changes in the fingerpulse wave were clearly dose-dependent, but it seems that this pharmacodynamic parameter is determined less by the plasma concentration than by the nitroglycerin content of the vascular wall.lld:pubmed
pubmed-article:6436032pubmed:languageenglld:pubmed
pubmed-article:6436032pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6436032pubmed:citationSubsetIMlld:pubmed
pubmed-article:6436032pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6436032pubmed:statusMEDLINElld:pubmed
pubmed-article:6436032pubmed:issn0031-6970lld:pubmed
pubmed-article:6436032pubmed:authorpubmed-author:FollathFFlld:pubmed
pubmed-article:6436032pubmed:authorpubmed-author:ImhofP RPRlld:pubmed
pubmed-article:6436032pubmed:authorpubmed-author:MüllerPPlld:pubmed
pubmed-article:6436032pubmed:authorpubmed-author:GérardinAAlld:pubmed
pubmed-article:6436032pubmed:authorpubmed-author:RacineAAlld:pubmed
pubmed-article:6436032pubmed:authorpubmed-author:VuilleminTTlld:pubmed
pubmed-article:6436032pubmed:issnTypePrintlld:pubmed
pubmed-article:6436032pubmed:volume27lld:pubmed
pubmed-article:6436032pubmed:ownerNLMlld:pubmed
pubmed-article:6436032pubmed:authorsCompleteYlld:pubmed
pubmed-article:6436032pubmed:pagination7-12lld:pubmed
pubmed-article:6436032pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:6436032pubmed:meshHeadingpubmed-meshheading:6436032-...lld:pubmed
pubmed-article:6436032pubmed:meshHeadingpubmed-meshheading:6436032-...lld:pubmed
pubmed-article:6436032pubmed:meshHeadingpubmed-meshheading:6436032-...lld:pubmed
pubmed-article:6436032pubmed:meshHeadingpubmed-meshheading:6436032-...lld:pubmed
pubmed-article:6436032pubmed:meshHeadingpubmed-meshheading:6436032-...lld:pubmed
pubmed-article:6436032pubmed:meshHeadingpubmed-meshheading:6436032-...lld:pubmed
pubmed-article:6436032pubmed:meshHeadingpubmed-meshheading:6436032-...lld:pubmed
pubmed-article:6436032pubmed:meshHeadingpubmed-meshheading:6436032-...lld:pubmed
pubmed-article:6436032pubmed:meshHeadingpubmed-meshheading:6436032-...lld:pubmed
pubmed-article:6436032pubmed:year1984lld:pubmed
pubmed-article:6436032pubmed:articleTitleStudies of the bioavailability of nitroglycerin from a transdermal therapeutic system (Nitroderm TTS).lld:pubmed
pubmed-article:6436032pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6436032lld:pubmed